Early detection of hepatocellular carcinoma (HCC) is clinically important because advanced HCC limits treatment modalities for the cancer. We have previously reported that serum levels of MAGE-4 protein are strongly associated with the development of HCC. The present study was designed to determine whether elevated serum MAGE-4 protein levels can predict hepatocellular carcinogenesis in patients with liver cirrhosis before clinical diagnosis. Among 62 cirrhotic patients, 28 patients were diagnosed with HCC during the follow-up period. The levels of MAGE-4 protein and α α α α-fetoprotein (AFP) were significantly elevated in cirrhotic patients with HCC.
Hepatocellular carcinoma (HCC) is usually caused by chronic inflammation of hepatocytes infected with hepatitis viruses. [1] [2] [3] Because HCC at an advanced stage with intrahepatic metastasis and/or vascular invasion is a serious graveyard disease, earlier detection of the development of HCC is clinically important. Although there are several markers of HCC, including α-fetoprotein (AFP) 4, 5) and aspartate aminotransferase (ALT), 6, 7) additional markers would be useful in managing high-risk groups, including those with chronic liver disease.
The MAGE gene family consists of at least 12 closely related genes located on the long arm of chromosome X. 8, 9) The MAGE-1, -2, -3, -4, -6, and -12 genes are preferentially expressed at the mRNA level in many different cancers. [8] [9] [10] [11] [12] [13] Normal cells, except for testicular cells, do not express the MAGE genes. 10, 11) We have previously reported that the MAGE-4 protein is detectable in patients with several types of cancers, including head and neck cancer, 14) lung cancer, 15) and ovarian cancer. 16) The protein is also detectable in certain liver cirrhosis (LC) patients with hepatitis C virus (HCV) infection, 17) suggesting that detection of the MAGE-4 protein in sera of LC patients could also be useful for early prediction of the development of HCC. In the present study, we compared MAGE-4 with AFP as a marker for HCC, and tested whether elevated serum MAGE-4 protein levels can be used to predict hepatocellular carcinogenesis in LC patients before clinical diagnosis.
MATERIALS AND METHODS
Patients and sample collection Sixty-two LC patients and 34 chronic hepatitis (CH) patients were enrolled in this study, and their profiles are shown in Table I . All patients were followed at either the Social Health Saga Hospital or the Kurume University Hospital. Sera of these patients was obtained from 1990 to 1999, and was frozen at −20°C until use. Diagnosis of HCC, LC, and CH was based on histological findings, ultrasonography, and computed tomography. Serum HCV markers were measured by enzyme-linked immunosorbent assay (ELISA) using anti-HCV antibody (PHA, Dinabot, Tokyo). Hepatitis B surface antigen (HBs-Ag) and HBc Ab were measured by enzyme-immunoassay (Misuho Medi, Tosu). Serum AFP levels were measured by radioimmunoassay (Dinabot). Detection of the MAGE-4 protein by ELISA Detection of the MAGE-4 protein in human sera was carried out by an ELISA using a mouse monoclonal antibody (mAb) (immunoglobulin (Ig) G1, R5) and a polyclonal rabbit affinity-purified IgG antibody against MAGE-4 protein, as previously reported. 11) In brief, the plate, which was coated with 10 µg/ml R5 mAb, was washed twice in TBS (100 mM Tris, 0.9% NaCl and 0.1% Tween 20, pH 7. 
RESULTS
Ninety-six patients with chronic liver disease were followed from 1990 to 1999. During this period, 28 of 62 LC patients (45%) were diagnosed as having developed HCC, while the other 34 CH patients did not develop the disease. These patients were classified into three groups: 28 LC patients with HCC, 34 LC patients without HCC, and 34 CH patients (Table I ). There was no statistical difference in age, gender, or percentage of HBs-Ag positive or HCV-Ab positive patients when these patients were enrolled in the study.
Because AFP is regarded as a marker for the development of HCC, 4, 5) we next compared the AFP and MAGE-4 levels of LC patients with or without HCC (Table II) . The follow-up period of the LC patients without HCC was significantly longer than that of the LC patients with HCC. The serum levels of MAGE-4 and AFP for the LC patients with HCC were significantly higher than those for the LC patients without HCC (P=0.0002 and 0.0161, respectively). Fig. 1 shows the MAGE-4 protein levels of the LC (Table III) . There was no difference in ALT levels between the two groups. With regard to AFP, high AFP levels were detected in 16 of 28 LC patients with HCC (57%) and 9 of the 34 LC patients without HCC (26%) (P=0.02). In contrast, 12 of 28 LC patients with HCC (43%) showed high MAGE-4 protein levels, and a significant increase in MAGE-4 protein levels was observed only in 2 of 34 LC patients (6%) without HCC (P=0.01). In addition, multivariate analysis using the logistic regression model was carried out to estimate the usefulness of the measurement of MAGE-4 (Table IV) . It was found that MAGE-4 protein levels are more significant than AFP levels. These results indicate that serum MAGE-4 protein levels could be a useful marker of HCC, even in comparison with AFP.
Furthermore, to determine whether measurement of serum MAGE-4 protein levels could be of use in predicting the development of hepatocellular carcinogenesis in cirrhotic patients, the kinetics of serum MAGE-4 protein in LC and CH patients were examined retrospectively (Fig. 2) . A continuous or transient increase in serum MAGE-4 protein levels was detected in 14 of the 28 LC patients who were subsequently diagnosed with HCC (50%) during the follow-up period (Fig. 2A) . Interestingly, tumor-reduction therapies, including percutaneous ethanol injection and transcatheter arterial embolization, resulted in a dramatic decrease in those protein levels in all six patients. In contrast, MAGE-4 levels increased up to a cutoff level only in 3 of 34 LC patients without HCC (Fig.  2B ) and in 2 of 34 CH patients (Fig. 2C) . Among the LC patients with HCC showing increased serum MAGE-4 levels, this increase was detected in most patients as long as 1 or 2 years before clinical diagnosis. These results suggest that increased serum MAGE-4 protein levels in LC patients can efficiently predict development of hepatocellular carcinogenesis.
DISCUSSION
MAGE genes are preferentially expressed in many different cancers. Other than testicular cells, however, no normal cells express the MAGE genes. We have recently shown that MAGE-4 protein is detectable in sera of patients with head-and-neck squamous-cell carcinoma, 14) with lung cancer, 15) and with ovarian cancer. 16) In addition, we have also found that elevated serum MAGE-4 protein levels are detectable in patients with HCV-related HCC. 17) Based on these findings, we tested the possibility that elevated serum MAGE-4 protein levels can predict development of hepatocellular carcinogenesis in cirrhotic patients before clinical diagnosis.
We first compared the usefulness of MAGE-4 and AFP as tumor markers. Although elevated serum AFP levels have been routinely applied as a parameter for HCC diagnosis, AFP transcripts are also detected in normal liver cells, in liver cirrhosis, and in liver infectious diseases such as HBV/HCV. 18) Indeed, fluctuating AFP levels in cirrhotic patients and the low specificity of AFP to HCC patients have been documented. 19) As shown in the present study, both AFP and MAGE-4 levels were significantly elevated in LC patients with HCC compared with those without HCC. However, MAGE-4 elevations were more significant than those of AFP in both univariate and multivariate analyses. These lines of evidence indicate that the serum MAGE-4 protein level could be a useful tumor marker to predict HCC, and that accurate diagnosis would be possible by combined measurement of serum MAGE-4 and AFP levels. However, a protein induced by vitamin K absence or antagonist-II (PIVKA-II) and AFP-L 3 were also reported as good indicators of HCC. 20, 21) We are planning to compare the usefulness of PIVKA-II, AFP-L 3 , and MAGE-4 as indicators of HCC.
We next tested the possibility that elevated serum MAGE-4 protein levels can predict hepatocellular carcino- genesis in cirrhotic patients before clinical diagnosis by retrospectively analyzing prefrozen sera of cirrhotic patients. As shown in Fig. 2 , a continuous or transient increase in serum MAGE-4 protein levels was detected in 50% of the LC patients with HCC. MAGE-4 levels increased in 9% and 6% of LC patients without HCC and in CH patients, respectively. It is of note that tumor-reduction therapies, including percutaneous ethanol injection and transcatheter arterial embolization, resulted in a dramatic decrease in MAGE-4 protein levels in HCC patients. A similar result was observed in the patients with headand-neck squamous-cell carcinomas. 14) Although we have not calculated the tumor volume of HCC, we speculate that the tumor size and the serum MAGE-4 protein level could be correlated. These results suggest that measurement of serum MAGE-4 levels could provide useful information for management of cirrhotic patients. In addressing why elevated serum MAGE-4 protein levels are detectable even a couple of years before clinical diagnosis, several explanations can be proposed. First, HCC producing MAGE-4 protein may already exist in patients whose tumor mass is too small for diagnosis by presently available methods. Second, HCV infection, which causes constitutive destruction of liver cells, may induce reproliferation of liver cells, and proliferating hepatocytes may produce MAGE-4 protein. This possibility is supported in part by the observation that the MAGE-4 gene is transiently expressed in the basal layer of the skin during would healing. 22) Further study, however, is needed to elucidate the precise mechanism.
In conclusion, we have demonstrated that measurement of serum MAGE-4 protein levels in LC patients is useful not only as a tumor marker, but also as a predictive marker of HCC. Measurement of serum MAGE-4 protein in highrisk groups, including LC patients, could facilitate prediction of HCC at an early stage when presently available methods are unable to detect HCC.
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